140 related articles for article (PubMed ID: 1382492)
21. [Combined treatment of metastatic endocrine tumors of the gastrointestinal tract with octreotide and interferon-alpha].
Nold R; Frank M; Kajdan U; Trost U; Klose KJ; Arnold R
Z Gastroenterol; 1994 Apr; 32(4):193-7. PubMed ID: 7517086
[TBL] [Abstract][Full Text] [Related]
22. Combined alpha- and gamma-interferon therapy for malignant midgut carcinoid tumors. A phase I-II trial.
Janson ET; Kauppinen HL; Oberg K
Acta Oncol; 1993; 32(2):231-3. PubMed ID: 8323762
[TBL] [Abstract][Full Text] [Related]
23. Treatment of metastatic carcinoid tumour with recombinant interferon alfa.
Joensuu H; Kumpulainen E; Gröhn P
Eur J Cancer; 1992; 28A(10):1650-3. PubMed ID: 1382493
[TBL] [Abstract][Full Text] [Related]
24. [Treatment of carcinoid syndrome with ocreotide (SMS-201-995)].
Rodríguez-García JL; Arechaga S; Fraile G; Serrano M
Rev Clin Esp; 1992 Jul; 191(3):168. PubMed ID: 1380173
[No Abstract] [Full Text] [Related]
25. Embolisation therapy in the midgut carcinoid syndrome: just tumour ischaemia?
Wängberg B; Geterud K; Nilsson O; Jansson S; Dahlström A; Tylén U; Ahlman H
Acta Oncol; 1993; 32(2):251-6. PubMed ID: 7686767
[TBL] [Abstract][Full Text] [Related]
26. The role of interferons in the management of carcinoid tumors.
Oberg K; Eriksson B
Acta Oncol; 1991; 30(4):519-22. PubMed ID: 1854509
[TBL] [Abstract][Full Text] [Related]
27. Management of disseminated midgut carcinoid tumours.
Ahlman H; Wängberg B; Jansson S; Stenqvist O; Geterud K; Tylén U; Caidahl K; Scherstén T; Tisell LE
Digestion; 1991; 49(2):78-96. PubMed ID: 1724766
[TBL] [Abstract][Full Text] [Related]
28. [A prolonged-action somatostatin analog and carcinoid syndrome].
Chayvialle JA
Bull Acad Natl Med; 1989 May; 173(5):643-50; discussion 650-1. PubMed ID: 2478266
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group.
di Bartolomeo M; Bajetta E; Buzzoni R; Mariani L; Carnaghi C; Somma L; Zilembo N; di Leo A
Cancer; 1996 Jan; 77(2):402-8. PubMed ID: 8625251
[TBL] [Abstract][Full Text] [Related]
30. Perianaesthetic risks and outcomes of abdominal surgery for metastatic carcinoid tumours.
Kinney MA; Warner ME; Nagorney DM; Rubin J; Schroeder DR; Maxson PM; Warner MA
Br J Anaesth; 2001 Sep; 87(3):447-52. PubMed ID: 11517130
[TBL] [Abstract][Full Text] [Related]
31. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide.
Oberg K; Norheim I; Theodorsson E
Acta Oncol; 1991; 30(4):503-7. PubMed ID: 1854508
[TBL] [Abstract][Full Text] [Related]
32. Treatment of carcinoid syndrome: a prospective crossover evaluation of lanreotide versus octreotide in terms of efficacy, patient acceptability, and tolerance.
O'Toole D; Ducreux M; Bommelaer G; Wemeau JL; Bouché O; Catus F; Blumberg J; Ruszniewski P
Cancer; 2000 Feb; 88(4):770-6. PubMed ID: 10679645
[TBL] [Abstract][Full Text] [Related]
33. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
[TBL] [Abstract][Full Text] [Related]
34. [Treatment with octreotide (SMS 201-995) in a case of intestinal carcinoid tumor].
Goñi F; Oleaga A; Goñi MJ; Monreal M; Yoldi A; González A; Llorente I; Moncada E
Rev Clin Esp; 1991 Nov; 189(7):331-4. PubMed ID: 1722585
[TBL] [Abstract][Full Text] [Related]
35. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome.
Rubin J; Ajani J; Schirmer W; Venook AP; Bukowski R; Pommier R; Saltz L; Dandona P; Anthony L
J Clin Oncol; 1999 Feb; 17(2):600-6. PubMed ID: 10080605
[TBL] [Abstract][Full Text] [Related]
36. Hepatic dearterialization in the treatment of carcinoid syndrome.
Sjöblom SM; Höckerstedt K; Järvinen H
Acta Chir Scand; 1987 Sep; 153(9):523-9. PubMed ID: 2447716
[TBL] [Abstract][Full Text] [Related]
37. Interferons alone or in combination with chemotherapy or other biologicals in the treatment of neuroendocrine gut and pancreatic tumors.
Oberg K; Eriksson B; Janson ET
Digestion; 1994; 55 Suppl 3():64-9. PubMed ID: 7698540
[TBL] [Abstract][Full Text] [Related]
38. Case report--carcinoid syndrome: two case reports from reserve unit.
Smith DF
J R Nav Med Serv; 2011; 97(2):66-71. PubMed ID: 22013639
[TBL] [Abstract][Full Text] [Related]
39. Interferon-alpha versus somatostatin or the combination of both in gastro-enteropancreatic tumours.
Oberg K
Digestion; 1996; 57 Suppl 1():81-3. PubMed ID: 8813477
[TBL] [Abstract][Full Text] [Related]
40. Treatment of malignant carcinoid tumors with human leukocyte interferon: long-term results.
Oberg K; Norheim I; Lind E; Alm G; Lundqvist G; Wide L; Jonsdottir B; Magnusson A; Wilander E
Cancer Treat Rep; 1986 Nov; 70(11):1297-304. PubMed ID: 2429764
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
